Clinical trials: Cancer Progression, open to volunteers
Moderate Aortic Valve Stenosis, Moderate Aortic Valve Regurgitation
Prospective Observational Cohort Study of Moderate Aortic Valve Disease
The objective of this research is to evaluate and predict the progression of moderate aortic stenosis and regurgitation from clinical characterization, biological, echocardiographic, and computed tomography (CT) et. al.
- Conditions
- Moderate Aortic Valve Stenosis, Moderate Aortic Valve Regurgitation, Aortic Valve Disease
- Trial name
- NCT06595992
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Coronary Artery Disease
MAIN-IMAGE Registry
All comers registry with patients with chronic coronary syndrome or acute coronary syndrome who underwent intracoronary imaging during cardiac catherization.
- Trial name
- MAIN-IMAGE (NCT06302777)
- Where
- 2 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Goethe University
Prostate Cancer (Adenocarcinoma), Vitamin D on Tumor Response and Inflammatory Markers
Comparative Analysis of Immunological Responses to Vitamin D Replacement Therapy in Black and West African Men Diagnosed With Prostate Cancer: Elucidating Differential Effects on Immune Function Between Patients With Localized Disease and Those With Metastatic Progression
This study is testing whether fixing vitamin D deficiency in Black/West African men with prostate cancer can strengthen their immune system, improve quality of life, and even slow cancer progression compared to those who remain…
- Trial name
- iCCaRE (NCT07598032)
- Testing
- vitamin D 25(OH)D
- Where
- Nigeria
- Volunteers
- 200 people
- Sponsor
- University of Ilorin Teaching Hospital
Diabetes Mellitus, Diabetes Mellitus, Type 1
Genetic Risk Score of Type 1 Diabetes Mellitus for Progression to Insulin in Diabetic Patients Lack of Predictive Value: a Multicenter Nested Case-control Study
The goal of this observational study is to evaluate the predictive value of the genetic risk score for type 1 diabetes in the progression to insulin deficiency in diabetic patients. The main question it aims to answer is: 1.
- Trial name
- NCT07621445
- Where
- China
- Volunteers
- 2,950 people
- Sponsor
- Second Xiangya Hospital of Central South University
Coronary Artery Disease, Coronary Artery Stenosis
Disease Characteristics of IR-CAD: a Case-control Study
The present case-control study is designed to investigate the disease characteristics of IR-CAD by comparing the demographics, clinical features, lab results, imaging findings, and prior treatment between 20 patients with IR-CAD…
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis, Coronary Artery Disease Progression
- Trial name
- NCT06007248
- Testing
- Protocol-defined Examinations
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Myopia
Influence of Rodenstock Spectacle Lenses on Myopia Progression.
The prevalence of myopia in Singapore is among the highest in the world, with 65 percent of our children being myopic by Primary 6, and 83 percent of young adults being myopic.
- Trial name
- NCT06816446
- Testing
- Myopia control spectacle lens, Single-vision lens
- Where
- Singapore
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Rodenstock GmbH
Clonal Cytopenia of Undetermined Significance
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
This phase II trial tests how well canakinumab works to prevent progression to cancer in patients with clonal cytopenias of unknown significance (CCUS). CCUS is a blood condition defined by a decrease in blood cells.
- Trial name
- NCT05641831
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Canakinumab
- Where
- 6 sites in United States
- Volunteers
- 110 people
- Sponsor
- Uma Borate
Myopia, Myopia, Progressive
Multicenter RCT: LED Red Light Dose-Response in Myopia Progression Control
The goal of this clinical trial is to verify the effectiveness and safety of non-laser LED red light combined with defocus lens therapy for controlling myopia progression and evaluate the impact of different intervention…
- Trial name
- NCT07330180
- Testing
- Yingtong Vision Rehabilitation Instrument, Hoya DIMS multi-point myopia defocus lens
- Where
- 7 sites in China
- Volunteers
- 364 people, healthy volunteers welcome
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
High Myopia
SmoothCore Orthokeratology Plus M.O.V.E. Lenses vs. M.O.V.E. Lenses Alone for Myopia Control in Children With High Myopia
This clinical trial aims to determine whether a combination of overnight orthokeratology lenses and daytime myopia-control spectacles is more effective than myopia-control spectacles alone in slowing myopia progression and…
- Trial name
- NCT07854366
- Testing
- SmoothCore Technology Orthokeratology Combined with M.O.V.E. Lenses, M.O.V.E. Lenses Alone
- Volunteers
- 100 people
- Sponsor
- Beijing Tongren Hospital
Liver Metastases, Hepatic Metastases
Therapeutic Efficacy and Safety of Ultrasound-Guided Microwave Ablation for Hepatic Metastatic Nodules
The liver is one of the most common organs where cancer cells spread (metastasize) from other parts of the body, especially from gastrointestinal cancers such as colorectal cancer.
- Conditions
- Liver Metastases, Hepatic Metastases, Secondary Malignant Neoplasm of Liver, Colorectal Cancer Metastatic
- Trial name
- NCT07871253
- Testing
- Ultrasound-Guided Microwave Ablation
- Volunteers
- 30 people
- Sponsor
- Assiut University
Glioma, Malignant
FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma
The goal of this clinical trial is to evaluate the performance characteristics of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in differentiating pseudoprogression from tumour progression in patients with equivocal conventional…
- Trial name
- FET PET in HGG (NCT06172595)
- Testing
- FET PET
- Where
- 2 sites in Singapore
- Volunteers
- 22 people
- Sponsor
- Singapore General Hospital
Acute Decompensation of Liver Cirrhosis, Established Acute-on-Chronic Liver Failure
Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure
Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients with Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure
- Trial name
- CONTROL-ACLF (NCT07694297)
- Testing
- NTZ 500mg BID on top of SOC
- Volunteers
- 16 people
- Sponsor
- Genfit
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
The goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for deficient mismatch repair (dMMR)/microsatellite…
- Conditions
- Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma
- Trial name
- Pan-MSI-ACSE (NCT06333314)
- Testing
- Dostarlimab, Chemotherapy
- Where
- 22 sites in France
- Volunteers
- 120 people
- Sponsor
- UNICANCER
AORTIC VALVE DISEASES, Calcification; Heart
Molecular Imaging to Identify Predictors of Aortic Valve Disease Activity
This is a prospective study that aims to develop clinical calculators that will report on the underlying rate of aortic valve calcification.
- Trial name
- NCT07819344
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Multiple Sclerosis (MS) - Relapsing-remitting
Effects of Ublituximab on Motor Functions in Multiple Sclerosis
The purpose of this study is to test if ublituximab changes walking functions and fall risk in people with relapsing multiple sclerosis (RMS). Twenty-five qualified people with RMS will undergo a 48-week ublituximab treatment.
- Trial name
- U-PACE (NCT06629428)
- Testing
- Ublituximab
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Georgia State University
Diabetic Nephropathies, Diabetic Glomerulosclerosis
Transformative Research in Diabetic Nephropathy
This is a prospective, observational, cohort study of patients with a clinical diagnosis of diabetes who are undergoing clinically indicated kidney biopsy.
- Trial name
- TRIDENT (NCT02986984)
- Testing
- There is no intervention
- Where
- 17 sites in United States
- Volunteers
- 400 people
- Sponsor
- University of Pennsylvania
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Di-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease
The goal of this interventional study is to evaluate the impact of a specific diet (low salt, limited caffeine, high potassium, low phosphate, limited protein, limited carbohydrate intake, adequate water intake) on changes in…
- Trial name
- ADPKD (NCT06786260)
- Testing
- Interventional Diet
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Loma Linda University
Carcinoma, Non-Small-Cell Lung
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy or in combination with Izalontamab Brengitecan in participants with advanced or metastatic Non-small Cell Lung Cancer…
- Trial name
- NCT06855771
- Testing
- BMS-986504, Izalontamab Brengitecan
- Where
- 67 sites in United States, Australia and 10 more
- Volunteers
- 182 people
- Sponsor
- Bristol-Myers Squibb
Urinary Bladder Neoplasms
Prospective Sample Collection for Cancer of Bladder
The goal of the Flemish Databank for Urothelial Cancer is to collect clinical and pathological data of patients treated for urothelial cancer (UC).
- Trial name
- ProCaB (NCT03973671)
- Where
- Belgium
- Volunteers
- 300 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven